SB0113 would amend Illinois pretrial release law to create a special rule for certain fentanyl-related drug charges. If a defendant is charged under the Illinois Controlled Substances Act with manufacturing, delivering, or possessing with intent to manufacture or deliver 15 grams or more of a substance containing fentanyl, or an analog, counterfeit substance, or controlled substance analog, the bill shifts the burden to the defendant to prove by clear and convincing evidence that pretrial release would not pose a real and present threat to the safety of any person or the community.
The bill makes this fentanyl-specific rule apply notwithstanding other provisions of the Code of Criminal Procedure. In practical terms, it would carve out these offenses from the general presumption that the State bears the burden at pretrial detention hearings, and it would make it easier for prosecutors to seek detention in qualifying fentanyl cases by requiring the accused to affirmatively show safety for release. The bill amends Sections 110-2 and 110-6.1 of the Code of Criminal Procedure of 1963 and would alter how courts evaluate pretrial release eligibility in these cases.
Impact
SB0113 would change Illinois pretrial detention standards by adding a new burden-shifting provision for fentanyl trafficking and related controlled-substance offenses at or above the 15-gram threshold. It would affect defendants charged with manufacture, delivery, or possession with intent to manufacture or deliver fentanyl-related substances, and it would give courts a statutory basis to treat those cases differently from the default pretrial release framework. The bill would amend the Code of Criminal Procedure of 1963, specifically Sections 110-2 and 110-6.1, and would likely affect prosecutors, defense counsel, judges, and defendants in serious drug cases.
Sentiment
Based on the bill text and the absence of committee testimony or recorded votes, the available context suggests the measure is framed as a public-safety response to fentanyl trafficking rather than a broad change to pretrial release policy. The sponsor’s caption and the bill’s structure indicate an intent to tighten detention standards for a narrow class of drug offenses. Because there is no transcript or voting history provided, no formal legislative sentiment can be measured from debate or roll calls, but the bill’s design reflects a tough-on-drugs, safety-focused approach.
Contention
The main point of contention is the bill’s departure from the general rule that the State bears the burden at pretrial detention hearings. SB0113 would require defendants in qualifying fentanyl cases to prove they are safe to release, which could be viewed by supporters as a necessary tool against high-risk drug trafficking and by opponents as a reversal of the usual presumption of release. Another likely issue is the bill’s use of a 15-gram threshold and its application to analogs and counterfeit substances, which could raise questions about scope, fairness, and whether the measure sweeps in defendants whose individual dangerousness may vary. No committee discussion is provided, so no specific named objections or supporters are available.